Bluefin Capital Management LLC Makes New $459,000 Investment in Pfizer Inc. $PFE

Bluefin Capital Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 19,056 shares of the biopharmaceutical company’s stock, valued at approximately $459,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Magnolia Capital Advisors LLC raised its holdings in shares of Pfizer by 4.5% during the 2nd quarter. Magnolia Capital Advisors LLC now owns 16,265 shares of the biopharmaceutical company’s stock worth $392,000 after buying an additional 705 shares in the last quarter. Port Capital LLC grew its position in Pfizer by 6.6% in the second quarter. Port Capital LLC now owns 9,442 shares of the biopharmaceutical company’s stock valued at $227,000 after acquiring an additional 583 shares during the last quarter. Freestone Grove Partners LP grew its position in Pfizer by 314.8% in the second quarter. Freestone Grove Partners LP now owns 335,530 shares of the biopharmaceutical company’s stock valued at $8,080,000 after acquiring an additional 254,644 shares during the last quarter. Gallagher Fiduciary Advisors LLC raised its stake in Pfizer by 4.3% during the second quarter. Gallagher Fiduciary Advisors LLC now owns 30,148 shares of the biopharmaceutical company’s stock worth $726,000 after acquiring an additional 1,235 shares in the last quarter. Finally, Western Wealth Management LLC lifted its holdings in shares of Pfizer by 5.9% in the second quarter. Western Wealth Management LLC now owns 82,496 shares of the biopharmaceutical company’s stock worth $1,987,000 after acquiring an additional 4,563 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. Wolfe Research restated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Citigroup raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research note on Tuesday, June 9th. Finally, Weiss Ratings downgraded shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer has started a European Medicines Agency review for its Lyme disease vaccine. The review is an important regulatory step that could expand Pfizer’s longer-term vaccine portfolio, although it does not guarantee approval or near-term revenue. Pfizer Starts EMA Review For Its Lyme Disease Vaccine
• Positive Sentiment: Recent comparisons with Bristol Myers Squibb suggest Pfizer’s valuation, diversification and oncology portfolio may offer an attractive risk-reward profile. This supports the view that the stock could benefit if new medicines successfully offset declining legacy-product sales. PFE vs BMY: Which Large Oncology Drugmaker Is a Better Stock Now?
• Positive Sentiment: Analysts are focused on Pfizer’s post-second-quarter pipeline and whether upcoming medicines can reset the company’s growth trajectory. The opportunity is meaningful because Pfizer recently exceeded quarterly earnings and revenue expectations, but execution remains key. How Is Pfizer Shaping Its S&P 500 Pipeline After Q2?
• Neutral Sentiment: Pfizer’s dividend remains appealing to income-oriented investors, but comparisons with Abbott Laboratories emphasize that Pfizer offers more turnaround potential while Abbott has a steadier dividend-growth record and broader diversification. Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
• Neutral Sentiment: Brokerages collectively rate Pfizer “Hold,” indicating that analysts see potential value but lack a strong consensus catalyst for a decisive re-rating. Pfizer Receives Consensus Recommendation of Hold
• Negative Sentiment: Investor caution persists over Pfizer’s need to restore growth before major patent expirations arrive. Articles discussing new medicines frame the pipeline as necessary to counterbalance expected pressure on established products, limiting enthusiasm until launches and approvals produce measurable results. Can New Medicines Reset the Growth Story?

Pfizer Stock Performance

NYSE:PFE opened at $28.33 on Thursday. The stock’s 50-day moving average is $25.44 and its 200-day moving average is $26.29. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market cap of $161.47 billion, a P/E ratio of 37.28 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business earned $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.